Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$14.89 USD
+0.21 (1.43%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $14.87 -0.02 (-0.13%) 7:58 PM ET
4-Sell of 5 4
B Value A Growth C Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CPRX 14.89 +0.21(1.43%)
Will CPRX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CPRX
Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
CPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
Other News for CPRX
Catalyst Pharma (CPRX) Receives a Buy from Truist Financial
20 companies screened for quality in a cheap part of the stock market
Edgewise gets EU orphan drug status for muscular dystrophy drug
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024